PDB Short entry for 1EVE HEADER SERINE HYDROLASE 04-MAR-98 1EVE TITLE THREE DIMENSIONAL STRUCTURE OF THE ANTI-ALZHEIMER DRUG, E2020 TITLE 2 (ARICEPT), COMPLEXED WITH ITS TARGET ACETYLCHOLINESTERASE COMPND MOL_ID: 1; COMPND 2 MOLECULE: ACETYLCHOLINESTERASE; COMPND 3 CHAIN: A; COMPND 4 EC: 3.1.1.7 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: TORPEDO CALIFORNICA; SOURCE 3 ORGANISM_COMMON: PACIFIC ELECTRIC RAY; SOURCE 4 ORGANISM_TAXID: 7787; SOURCE 5 VARIANT: G2 FORM; SOURCE 6 ORGAN: ELECTRIC ORGAN; SOURCE 7 TISSUE: ELECTROPLAQUE KEYWDS ALZHEIMER'S DISEASE, DRUG, SERINE HYDROLASE, ALPHA/BETA HYDROLASE, KEYWDS 2 NEUROTRANSMITTER CLEAVAGE, CATALYTIC TRIAD, GLYCOSYLATED PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR G.KRYGER,I.SILMAN,J.L.SUSSMAN REVDAT 6 09-AUG-23 1EVE 1 HETSYN REVDAT 5 29-JUL-20 1EVE 1 COMPND REMARK HETNAM LINK REVDAT 5 2 1 SITE ATOM REVDAT 4 13-JUL-11 1EVE 1 VERSN REVDAT 3 24-FEB-09 1EVE 1 VERSN REVDAT 2 22-MAR-99 1EVE 1 JRNL REVDAT 1 20-JAN-99 1EVE 0 JRNL AUTH G.KRYGER,I.SILMAN,J.L.SUSSMAN JRNL TITL STRUCTURE OF ACETYLCHOLINESTERASE COMPLEXED WITH E2020 JRNL TITL 2 (ARICEPT): IMPLICATIONS FOR THE DESIGN OF NEW ANTI-ALZHEIMER JRNL TITL 3 DRUGS. JRNL REF STRUCTURE FOLD.DES. V. 7 297 1999 JRNL REFN ISSN 0969-2126 JRNL PMID 10368299 JRNL DOI 10.1016/S0969-2126(99)80040-9 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH Y.KAWAKAMI,A.INOUE,T.KAWAI,M.WAKITA,H.SUGIMOTO,A.J.HOPFINGER REMARK 1 TITL THE RATIONALE FOR E2020 AS A POTENT ACETYLCHOLINESTERASE REMARK 1 TITL 2 INHIBITOR REMARK 1 REF BIOORG.MED.CHEM. V. 4 1429 1996 REMARK 1 REFN ISSN 0968-0896 REMARK 1 REFERENCE 2 REMARK 1 AUTH J.L.SUSSMAN,M.HAREL,F.FROLOW,C.OEFNER,A.GOLDMAN,L.TOKER, REMARK 1 AUTH 2 I.SILMAN REMARK 1 TITL ATOMIC STRUCTURE OF ACETYLCHOLINESTERASE FROM TORPEDO REMARK 1 TITL 2 CALIFORNICA: A PROTOTYPIC ACETYLCHOLINE-BINDING PROTEIN REMARK 1 REF SCIENCE V. 253 872 1991 REMARK 1 REFN ISSN 0036-8075 REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR 3.851 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 10000000.000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0010 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 98.3 REMARK 3 NUMBER OF REFLECTIONS : 34240 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.188 REMARK 3 FREE R VALUE : 0.228 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.800 REMARK 3 FREE R VALUE TEST SET COUNT : 1976 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.005 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.66 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 97.70 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 5288 REMARK 3 BIN R VALUE (WORKING SET) : 0.2860 REMARK 3 BIN FREE R VALUE : 0.3670 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.30 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 295 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.021 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4254 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 98 REMARK 3 SOLVENT ATOMS : 396 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 39.10 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 29.30 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.06000 REMARK 3 B22 (A**2) : 1.06000 REMARK 3 B33 (A**2) : -2.13000 REMARK 3 B12 (A**2) : -0.48000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.25 REMARK 3 ESD FROM SIGMAA (A) : 0.30 REMARK 3 LOW RESOLUTION CUTOFF (A) : 30.0 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.30 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.39 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 1.200 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 23.10 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.970 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 3.100 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 4.590 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 5.130 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 6.880 ; 2.500 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PARHCSDX.PRO REMARK 3 PARAMETER FILE 2 : PARAM19.SOL REMARK 3 PARAMETER FILE 3 : CBH3.PARAM REMARK 3 PARAMETER FILE 4 : LEARN.E2020 REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : TOPHCSDX.PRO REMARK 3 TOPOLOGY FILE 2 : TOPH11.WAT REMARK 3 TOPOLOGY FILE 3 : E2020.TOP REMARK 3 TOPOLOGY FILE 4 : CBH3-P.CHO REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: BULK SOLVENT MODEL USED REMARK 4 REMARK 4 1EVE COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000173183. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : MAY-97 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RUH3R REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NI FILTER REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 34266 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.500 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.1 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.05000 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.59 REMARK 200 COMPLETENESS FOR SHELL (%) : 95.0 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.25200 REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: X-PLOR 3.851 REMARK 200 STARTING MODEL: PDB ENTRY 2ACE REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 68.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.80 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 5.8 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 31 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+2/3 REMARK 290 6555 -X,-X+Y,-Z+1/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 45.63200 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 91.26400 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 91.26400 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 45.63200 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: TORPEDO CALIFORNICA ACETYLCHOLINESTERASE IS A G2 DIMER IN REMARK 300 SOLUTION (SEE SUSSMAN 1988). THE ASYMMETRIC UNIT CONTAINS REMARK 300 A MONOMER, WITH THE CRYSTALLOGRAPHIC TWO-FOLD AXIS RELATING REMARK 300 THE TWO MONOMERS IN A DIMER. THIS STRUCTURE IS MORE REMARK 300 COMPLETE THAN THE STARTING MODEL OF THE NATIVE STRUCTURE REMARK 300 (PDB ID 2ACE). RESIDUES THAT ARE NOT SEEN IN THE CRYSTAL REMARK 300 STRUCTURE DUE TO DISORDER INCLUDE THE N-TERMINAL RESIDUE REMARK 300 ASP 1 AND THE C-TERMINAL RESIDUES AFTER THR 535. THR 535 REMARK 300 IS THE LAST RESIDUE OBSERVED AT THE C-TERMINUS. THE LIGAND REMARK 300 SEEN IN THE STRUCTURE, E2020 (DONEPEZIL, ARICEPT), IS A REMARK 300 POTENT REVERSIBLE ACHE INHIBITOR WHICH IS AN FDA APPROVED REMARK 300 DRUG FOR THE SYMPTOMATIC TREATMENT OF ALZHEIMER'S DISEASE REMARK 300 (SEE KAWAKAMI 1996). THE CHIRAL INHIBITOR WAS SOAKED AS A REMARK 300 RACEMATE BUT ONLY THE R FORM SEEMS TO BIND TO THE ENZYME REMARK 300 ACCORDING TO THE X-RAY DIFFRACTION EXPERIMENT. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A1381 LIES ON A SPECIAL POSITION. REMARK 375 HOH A1382 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ASP A 1 REMARK 465 ALA A 536 REMARK 465 CYS A 537 REMARK 465 ASP A 538 REMARK 465 GLY A 539 REMARK 465 GLU A 540 REMARK 465 LEU A 541 REMARK 465 SER A 542 REMARK 465 SER A 543 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ASP A 2 CG OD1 OD2 REMARK 470 HIS A 3 CG ND1 CD2 CE1 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 HIS A 3 -94.75 -131.86 REMARK 500 SER A 24 -24.45 74.01 REMARK 500 SER A 25 -165.83 -101.45 REMARK 500 PRO A 39 40.38 -74.51 REMARK 500 PHE A 45 -13.15 80.73 REMARK 500 ALA A 60 52.02 -116.78 REMARK 500 SER A 108 81.90 -161.75 REMARK 500 ALA A 164 72.79 -156.57 REMARK 500 SER A 200 -112.92 55.47 REMARK 500 SER A 291 -71.17 -57.73 REMARK 500 THR A 317 -162.98 -163.72 REMARK 500 ASP A 326 77.34 -119.92 REMARK 500 HIS A 362 20.32 -79.31 REMARK 500 ASP A 380 66.96 -159.21 REMARK 500 VAL A 400 -66.25 -126.27 REMARK 500 LYS A 498 -63.59 -90.42 REMARK 500 ARG A 515 70.10 49.62 REMARK 500 REMARK 500 REMARK: NULL REMARK 650 REMARK 650 HELIX REMARK 650 THE ENZYME IS A GPI-ANCHORED DIMER, THE TWO MONOMERS IN THE REMARK 650 DIMER ARE RELATED BY CRYSTALLOGRAPHIC TWO-FOLD SYMMETRY AND REMARK 650 GENERATE A FOUR HELIX BUNDLE A365-A375 AND A518-A535. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: CAT REMARK 800 EVIDENCE_CODE: UNKNOWN REMARK 800 SITE_DESCRIPTION: CATALYTIC TRIAD. REMARK 800 REMARK 800 SITE_IDENTIFIER: IHB REMARK 800 EVIDENCE_CODE: UNKNOWN REMARK 800 SITE_DESCRIPTION: INHIBITOR BINDING SITE. DBREF 1EVE A 1 543 UNP P04058 ACES_TORCA 22 564 SEQRES 1 A 543 ASP ASP HIS SER GLU LEU LEU VAL ASN THR LYS SER GLY SEQRES 2 A 543 LYS VAL MET GLY THR ARG VAL PRO VAL LEU SER SER HIS SEQRES 3 A 543 ILE SER ALA PHE LEU GLY ILE PRO PHE ALA GLU PRO PRO SEQRES 4 A 543 VAL GLY ASN MET ARG PHE ARG ARG PRO GLU PRO LYS LYS SEQRES 5 A 543 PRO TRP SER GLY VAL TRP ASN ALA SER THR TYR PRO ASN SEQRES 6 A 543 ASN CYS GLN GLN TYR VAL ASP GLU GLN PHE PRO GLY PHE SEQRES 7 A 543 SER GLY SER GLU MET TRP ASN PRO ASN ARG GLU MET SER SEQRES 8 A 543 GLU ASP CYS LEU TYR LEU ASN ILE TRP VAL PRO SER PRO SEQRES 9 A 543 ARG PRO LYS SER THR THR VAL MET VAL TRP ILE TYR GLY SEQRES 10 A 543 GLY GLY PHE TYR SER GLY SER SER THR LEU ASP VAL TYR SEQRES 11 A 543 ASN GLY LYS TYR LEU ALA TYR THR GLU GLU VAL VAL LEU SEQRES 12 A 543 VAL SER LEU SER TYR ARG VAL GLY ALA PHE GLY PHE LEU SEQRES 13 A 543 ALA LEU HIS GLY SER GLN GLU ALA PRO GLY ASN VAL GLY SEQRES 14 A 543 LEU LEU ASP GLN ARG MET ALA LEU GLN TRP VAL HIS ASP SEQRES 15 A 543 ASN ILE GLN PHE PHE GLY GLY ASP PRO LYS THR VAL THR SEQRES 16 A 543 ILE PHE GLY GLU SER ALA GLY GLY ALA SER VAL GLY MET SEQRES 17 A 543 HIS ILE LEU SER PRO GLY SER ARG ASP LEU PHE ARG ARG SEQRES 18 A 543 ALA ILE LEU GLN SER GLY SER PRO ASN CYS PRO TRP ALA SEQRES 19 A 543 SER VAL SER VAL ALA GLU GLY ARG ARG ARG ALA VAL GLU SEQRES 20 A 543 LEU GLY ARG ASN LEU ASN CYS ASN LEU ASN SER ASP GLU SEQRES 21 A 543 GLU LEU ILE HIS CYS LEU ARG GLU LYS LYS PRO GLN GLU SEQRES 22 A 543 LEU ILE ASP VAL GLU TRP ASN VAL LEU PRO PHE ASP SER SEQRES 23 A 543 ILE PHE ARG PHE SER PHE VAL PRO VAL ILE ASP GLY GLU SEQRES 24 A 543 PHE PHE PRO THR SER LEU GLU SER MET LEU ASN SER GLY SEQRES 25 A 543 ASN PHE LYS LYS THR GLN ILE LEU LEU GLY VAL ASN LYS SEQRES 26 A 543 ASP GLU GLY SER PHE PHE LEU LEU TYR GLY ALA PRO GLY SEQRES 27 A 543 PHE SER LYS ASP SER GLU SER LYS ILE SER ARG GLU ASP SEQRES 28 A 543 PHE MET SER GLY VAL LYS LEU SER VAL PRO HIS ALA ASN SEQRES 29 A 543 ASP LEU GLY LEU ASP ALA VAL THR LEU GLN TYR THR ASP SEQRES 30 A 543 TRP MET ASP ASP ASN ASN GLY ILE LYS ASN ARG ASP GLY SEQRES 31 A 543 LEU ASP ASP ILE VAL GLY ASP HIS ASN VAL ILE CYS PRO SEQRES 32 A 543 LEU MET HIS PHE VAL ASN LYS TYR THR LYS PHE GLY ASN SEQRES 33 A 543 GLY THR TYR LEU TYR PHE PHE ASN HIS ARG ALA SER ASN SEQRES 34 A 543 LEU VAL TRP PRO GLU TRP MET GLY VAL ILE HIS GLY TYR SEQRES 35 A 543 GLU ILE GLU PHE VAL PHE GLY LEU PRO LEU VAL LYS GLU SEQRES 36 A 543 LEU ASN TYR THR ALA GLU GLU GLU ALA LEU SER ARG ARG SEQRES 37 A 543 ILE MET HIS TYR TRP ALA THR PHE ALA LYS THR GLY ASN SEQRES 38 A 543 PRO ASN GLU PRO HIS SER GLN GLU SER LYS TRP PRO LEU SEQRES 39 A 543 PHE THR THR LYS GLU GLN LYS PHE ILE ASP LEU ASN THR SEQRES 40 A 543 GLU PRO MET LYS VAL HIS GLN ARG LEU ARG VAL GLN MET SEQRES 41 A 543 CYS VAL PHE TRP ASN GLN PHE LEU PRO LYS LEU LEU ASN SEQRES 42 A 543 ALA THR ALA CYS ASP GLY GLU LEU SER SER MODRES 1EVE ASN A 59 ASN GLYCOSYLATION SITE MODRES 1EVE ASN A 416 ASN GLYCOSYLATION SITE MODRES 1EVE ASN A 533 ASN GLYCOSYLATION SITE MODRES 1EVE ASN A 457 ASN GLYCOSYLATION SITE HET NAG B 1 14 HET NAG B 2 14 HET NAG A3001 14 HET NAG A3004 14 HET NAG A3005 14 HET E20 A2001 28 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETNAM E20 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL) HETNAM 2 E20 METHYL]PIPERIDINE HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE HETSYN E20 E2020 FORMUL 2 NAG 5(C8 H15 N O6) FORMUL 6 E20 C24 H29 N O3 FORMUL 7 HOH *396(H2 O) HELIX 1 1 GLY A 41 MET A 43 5 3 HELIX 2 2 SER A 79 TRP A 84 1 6 HELIX 3 3 ASP A 128 TYR A 130 5 3 HELIX 4 4 LYS A 133 GLU A 139 1 7 HELIX 5 5 GLY A 151 PHE A 155 1 5 HELIX 6 6 VAL A 168 PHE A 187 1 20 HELIX 7 7 ALA A 201 LEU A 211 1 11 HELIX 8 8 PRO A 213 LEU A 218 1 6 HELIX 9 9 VAL A 238 LEU A 252 1 15 HELIX 10 10 ASP A 259 GLU A 268 1 10 HELIX 11 11 PRO A 271 VAL A 281 1 11 HELIX 12 12 LEU A 305 SER A 311 1 7 HELIX 13 13 SER A 329 GLY A 335 1 7 HELIX 14 14 ARG A 349 SER A 359 1 11 HELIX 15 15 ASP A 365 GLN A 374 1 10 HELIX 16 16 GLY A 384 ASN A 399 1 16 HELIX 17 17 ILE A 401 PHE A 414 1 14 HELIX 18 18 GLU A 434 MET A 436 5 3 HELIX 19 19 ILE A 444 VAL A 447 1 4 HELIX 20 20 LEU A 450 LEU A 452 5 3 HELIX 21 21 LYS A 454 LEU A 456 5 3 HELIX 22 22 ALA A 460 THR A 479 1 20 HELIX 23 23 VAL A 518 ASN A 525 1 8 HELIX 24 24 PHE A 527 ASN A 533 1 7 SHEET 1 A 3 LEU A 6 THR A 10 0 SHEET 2 A 3 GLY A 13 MET A 16 -1 N VAL A 15 O VAL A 8 SHEET 3 A 3 VAL A 57 ALA A 60 1 N TRP A 58 O LYS A 14 SHEET 1 B11 MET A 16 PRO A 21 0 SHEET 2 B11 HIS A 26 PRO A 34 -1 O ALA A 29 N THR A 18 SHEET 3 B11 TYR A 96 PRO A 102 -1 N ILE A 99 O PHE A 30 SHEET 4 B11 VAL A 142 SER A 147 -1 N LEU A 143 O TRP A 100 SHEET 5 B11 THR A 109 TYR A 116 1 N MET A 112 O VAL A 142 SHEET 6 B11 THR A 193 GLU A 199 1 O THR A 195 N VAL A 113 SHEET 7 B11 ARG A 220 SER A 226 1 N ILE A 223 O ILE A 196 SHEET 8 B11 GLN A 318 ASN A 324 1 N GLY A 322 O LEU A 224 SHEET 9 B11 GLY A 417 PHE A 423 1 N TYR A 421 O LEU A 321 SHEET 10 B11 PHE A 502 LEU A 505 1 N ILE A 503 O LEU A 420 SHEET 11 B11 MET A 510 GLN A 514 -1 N HIS A 513 O PHE A 502 SSBOND 1 CYS A 67 CYS A 94 1555 1555 2.03 SSBOND 2 CYS A 254 CYS A 265 1555 1555 2.03 SSBOND 3 CYS A 402 CYS A 521 1555 1555 2.03 LINK ND2 ASN A 59 C1 NAG A3001 1555 1555 1.46 LINK ND2 ASN A 416 C1 NAG B 1 1555 1555 1.44 LINK ND2 ASN A 457 C1 NAG A3005 1555 1555 1.46 LINK ND2 ASN A 533 C1 NAG A3004 1555 1555 1.46 LINK O4 NAG B 1 C1 NAG B 2 1555 1555 1.41 CISPEP 1 SER A 103 PRO A 104 0 -0.32 SITE 1 CAT 3 SER A 200 GLU A 327 HIS A 440 SITE 1 IHB 3 TRP A 84 PHE A 330 TRP A 279 CRYST1 111.925 111.925 136.896 90.00 90.00 120.00 P 31 2 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.008935 0.005158 0.000000 0.00000 SCALE2 0.000000 0.010317 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007305 0.00000